EUVIMEDEUVIMED entdecken
Open Access

Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease

Christina VanderPluym, Paul Esteso, Ashish Ankola, Amy Hellinger, Courtney Ventresco, Beth Hawkins, Ryan L Kobayashi, Ryan Williams, Maria A Cetatoiu, Kimberlee Gauvreau, Jesse J Esch

Journal of Thrombosis and Haemostasis · 2023-06 · 21 (6) · 1601-1609

DOI: 10.1016/j.jtha.2023.03.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2023-06. Verfasst von Christina VanderPluym und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart Center, Boston Children's Hospital, Harvard School of Medicine, Boston, Massachusetts, USA; Harvard School of Medicin…. Hauptthemen laut MEDLINE: Venous Thromboembolism, Thrombosis, Heart Diseases. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Direct oral anticoagulants use in pediatric cardiology is poorly defined. OBJECTIVE: We present the largest experience of apixaban use in children with heart disease, using weight- and level-based dosing. METHODS: Retrospective single-center analysis of cardiac patients ≤19 years treated with apixaban. Patients were evaluated for safety (clinically relevant non-major [CRNM] or major bleeding; thrombotic events) and effectiveness (thrombus improvement by imaging). Peak drug-specific anti-Xa chromogenic assay results ("apixaban levels") were analyzed. RESULTS: Over 3 years (5/2018-9/2021), 219 children, median age 6.8 years (0.3-19), median weight 20.8 kg (4.8-160) received apixaban, totaling 50,916 patient days. Of them, 172 (79%) warranted thromboprophylaxis and 47 (21%) thrombosis treatment (with 10 arterial, 19 venous, 15 intracardiac, and 3 pulmonary). The median initial peak apixaban level was 165 ng/mL (23-474; n = 125) in the prophylaxis subgroup and 153 ng/mL (30-450; n = 33) in the treatment subgroup; dosage was adjusted in response to levels in 25% of the patients. There were 4 bleeding safety events (3 CRNM; 1 major, hemoptysis complicating empyema); the serious bleeding event rate was 2.9 per 100 patient-years of apixaban. Minor bleeding events (42) were noted in 18 patients, with an additional 2 having leukopenia, 1 transaminitis, and 3 rashes. An improvement in thrombosis was seen in 95% of the treated patients with available follow-up imaging (37/39 patients). CONCLUSION: Apixaban use was feasible with a low rate of adverse events across a diverse pediatric cardiac population using commercially available tablets dosed to weight and adjusted based on peak apixaban levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismThrombosisHeart DiseasesHumansChildAnticoagulantsWarfarinRetrospective StudiesHemorrhagePyridonesFactor Xa InhibitorsPyrazoles

Stichwörter der Autor:innen

DOACapixabanchildrencongenital heart diseasethrombosis

Substanzen

AnticoagulantsWarfarinPyridonesFactor Xa InhibitorsapixabanPyrazoles

Autor:innen und Institutionen

  • Department of Cardiology, Heart Center, Boston Children's Hospital, Harvard School of Medicine, Boston, Massachusetts, USA; Harvard School of Medicine, Boston, Massachusetts, USA. Electronic address: Christina.vanderplu…
  • Department of Cardiology, Heart Center, Boston Children's Hospital, Harvard School of Medicine, Boston, Massachusetts, USA; Harvard School of Medicine, Boston, Massachusetts, USA.
  • Department of Intensive Care, Texas Children's Hospital, Houston, Texas, USA.
  • Department of Cardiology, Heart Center, Boston Children's Hospital, Harvard School of Medicine, Boston, Massachusetts, USA.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

VanderPluym, C., Esteso, P., Ankola, A., Hellinger, A., Ventresco, C., Hawkins, B., Kobayashi, R. L., Williams, R., Cetatoiu, M. A., Gauvreau, K., & Esch, J. J. (2023). Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. Journal of Thrombosis and Haemostasis, 21(6), 1601-1609. https://doi.org/10.1016/j.jtha.2023.03.005

Vancouver

VanderPluym C, Esteso P, Ankola A, Hellinger A, Ventresco C, Hawkins B, et al. Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. Journal of Thrombosis and Haemostasis. 2023;21(6):1601-1609. doi:10.1016/j.jtha.2023.03.005

BibTeX
@article{VanderPluym2023,
  author = {VanderPluym, Christina and Esteso, Paul and Ankola, Ashish and Hellinger, Amy and Ventresco, Courtney and Hawkins, Beth and Kobayashi, Ryan L and Williams, Ryan and Cetatoiu, Maria A and Gauvreau, Kimberlee and Esch, Jesse J},
  title = {Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2023},
  volume = {21},
  number = {6},
  pages = {1601--1609},
  doi = {10.1016/j.jtha.2023.03.005}
}
Kostenlos starten →